Doctors injected one tumor and watched cancer vanish body-wide, offering real hope against deadly diseases without the government overreach of past failed policies.
Story Highlights
- Rockefeller University’s 2141-V11 immunotherapy shrank tumors in 50% of phase 1 patients and achieved complete remission in two with aggressive melanoma and breast cancer.
- Direct tumor injection triggers an immune attack on distant tumors, bypassing toxic IV methods that plagued prior therapies.
- Ongoing trials with nearly 200 patients target bladder, prostate, and glioblastoma cancers at top U.S. institutions.
- Minimal side effects mark a safe advance, validating American innovation over bureaucratic red tape.
Phase 1 Trial Delivers Remarkable Results
Researchers at Rockefeller University tested 2141-V11, a modified CD40 agonist antibody, in 12 patients with metastatic cancers. They injected the drug directly into one tumor.
Six patients saw tumor shrinkage. Two achieved complete remission—one with melanoma featuring dozens of leg tumors, the other with metastatic breast cancer.
All distant tumors disappeared after targeting a single site. No severe side effects occurred, unlike past CD40 drugs given intravenously. This local delivery concentrates power where needed, sparking body-wide immune response. Patients gained new life from this precise approach.
Breakthroughs like this are why sustained investment in biomedical science matters.
In an early trial, injecting immunotherapy into one tumor triggered immune responses across the body – with 50% of patients responding and some complete remissions.
Science saves lives. pic.twitter.com/V26f705tou
— Dr. Catharine Young (@DrCatharineY) March 18, 2026
Innovation Overcomes Decades of Setbacks
CD40 agonists failed for years due to systemic toxicity from IV administration, as CD40 receptors cover healthy tissues. Jeffrey Ravetch’s team at the Leonard Wagner Laboratory redesigned the antibody to increase its potency.
They shifted to intratumoral injection to minimize exposure of healthy tissue. Juan Osorio, first author and oncologist at Memorial Sloan Kettering, noted the rarity of such responses in small trials.
Treated tumors formed tertiary lymphoid structures that mimicked lymph nodes, sustaining immune attacks. High baseline T cell clonality predicted success, pointing to future patient selection.
Expanded Trials Test Broader Impact
Phase 1 and 2 trials now enroll nearly 200 patients across Rockefeller University, Memorial Sloan Kettering, and Duke University. These studies target bladder cancer, prostate cancer, and glioblastoma—tough foes with few options.
Ravetch described injecting one thigh tumor in a melanoma patient, eliminating all others on the leg and foot. Osorio called the shrinkages and remissions remarkable.
Larger cohorts will confirm response rates, biomarkers, and safety. Success could reshape treatment for accessible tumors, prioritizing targeted efficacy over blanket therapies.
Immunotherapy advances fit President Trump’s push for American innovation. Under his leadership, reduced regulations freed researchers from leftist overregulation that stalled progress.
Five-year cancer survival hit 70%, with melanoma rates doubling to 35% via prior immunotherapies. This builds on that momentum, countering globalist distractions with homegrown breakthroughs.
Families facing cancer see real victories, not empty promises from big-government spending sprees. Parallel efforts like UCLA’s CAR-NKT cells and KAIST’s CAR-macrophages show converging science, but Rockefeller leads with human data.
New Cancer Immunotherapy Killed Whole Tumors
Researchers at Rockefeller University are reporting encouraging results from an early clinical trial of a redesigned cancer immunotherapy that is injected directly into tumors.
In the small study, six of 12 patients experienced…
— NENE'S MOMMA (@DebrulerTerri) March 18, 2026
Path Forward Amid Cautious Optimism
Limited phase 1 data demands larger validation, as only 12 patients participated. Long-term remission durability awaits follow-up. Mechanism details, such as the exact systemic spread, require further study.
FDA oversight under Trump ensures swift, safe paths without Biden-era delays. Oncologists must adapt to biomarkers like T cell clonality.
Patients with metastatic disease stand to benefit most, gaining options beyond chemo’s toll. This promises personalized care, aligning with conservative values of self-reliance and family strength in the face of illness.
Sources:
Rockefeller University (ScienceDaily)
Private Health on Immunotherapy Breakthroughs
